Phase I Study -To Assess Safety and Feasibility of IL-8 Receptor Modified Patient-derived Activated CD70 CAR T Cell Therapy in CD70+ Adult GBM and Pediatric High-Grade Gliomas (pHGG)
This study tests a new type of immunotherapy for adults with a fast-growing and aggressive type of brain tumor called glioblastoma. The goal is to see if a special treatment using modified immune cells is safe and feasible for patients.
Adults 18 and older with a newly diagnosed, single primary brain tumor in the upper part of the brain that tests positive for the CD70 protein marker may be eligible. Participants must also be in overall good enough health to receive cell-based treatments.
Your own immune cells will be collected, grown in a lab, and modified to better target your cancer before being given back to you as a treatment. Doctors will closely monitor your safety and health throughout the process.
The study is taking place in Gainesville, Florida, United States, and is currently active but not recruiting new participants.
- 1Tests an advanced immunotherapy treatment using your own immune cells
- 2Specifically designed for adults with a newly diagnosed aggressive brain tumor
- 3Currently active in Gainesville, Florida, but not actively recruiting new patients
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.